Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C10H14N2O4
CAS Number:
Molecular Weight:
226.23
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352202
EC Number:
249-271-9
MDL number:
InChI key
TZFNLOMSOLWIDK-JTQLQIEISA-N
InChI
1S/C10H14N2O4/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6/h2-4,12-14H,5,11H2,1H3,(H,15,16)/t10-/m0/s1
SMILES string
CC(Cc1ccc(O)c(O)c1)(NN)C(O)=O
assay
≥98% (TLC)
form
powder
solubility
methanol and 1 drop HCl: 4.90-5.10 mg/mL, clear, colorless to faintly yellow
storage temp.
−20°C
Quality Level
Gene Information
human ... DDC(1644)
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
Carbidopa is used for treating restless legs (RL) syndrome and periodic leg movements in sleep (PLMS). Carbidopa along with levodopa is used to treat Parkinson′s disease.
Biochem/physiol Actions
Peripheral inhibitor of L-aromatic amino acid decarboxylase.
Peripheral inhibitor of L-aromatic amino acid decarboxylase. When co-administered with L-DOPA, it prevents extra-CNS conversion to dopamine, thereby increasing CNS concentrations of effective compounds. Selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells by increasing H2O2 in these cell lines, which are sensitive to reactive oxygen species.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Levodopa with benserazide or carbidopa in Parkinson disease
Rinne UK and Molsa P
Neurology, 29(12), 1584-1589 (1979)
Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients
Earley CJ and Allen RP
Sleep, 19(10), 801-810 (1996)
V K Datieva et al.
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 112(10 Pt 2), 13-19 (2012-12-20)
The objective of this multicenter observational study "Optimization levodopa therapy for patients with Parkinson's disease" (OPTIMA) was to evaluate the current practice of prescribing levodopa to patients with Parkinson's disease (PD) by general practitioners and specialists in the treatment of
S Kaakkola et al.
Journal of neurochemistry, 60(1), 137-144 (1993-01-01)
The effects of two new catechol-O-methyltransferase (COMT) inhibitors, OR-611 and Ro 40-7592, in combination with L-3,4-dihydroxyphenylalanine (L-dopa) with or without carbidopa on extracellular levels of dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 3-O-methyldopa (3-OMD), and 5-hydroxyindoleacetic acid in rat
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.
Hubert H Fernandez et al.
Parkinsonism & related disorders, 19(3), 339-345 (2013-01-05)
Levodopa-carbidopa intestinal gel (LCIG) delivered continuously via percutaneous endoscopic gastrojejunostomy (PEG-J) tube has been reported, mainly in small open-label studies, to significantly alleviate motor complications in Parkinson's disease (PD). A prospective open-label, 54-week, international study of LCIG is ongoing in
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service